Shire plc (SHPGY) Stock Research, Analysis & News
Quick Analysis on Shire plc (SHPGY) Stock as of May 18, 2012
 | Previous Closing Price $91.69 is below its 50 day moving average $96.04 |
| Previous Closing Price $91.69 is below its 200 day moving average $99.65 |
 | The Price/Earnings To Growth ratio (PEG) is great than 1 |
| The Stock pays a dividend of 0.49% |
| The closing price $91.69 is more than 23.33% away from its one year target price of $113.08 |
(See more information about Shire plc (SHPGY) Stock below)
Shire plc (SHPGY) Stock Profile Summary
Shire plc, together with subsidiaries, engages in the research, development, manufacture, sale, and distribution of pharmaceutical products. The company operates through two segments: Specialty Pharmaceuticals and Human Genetic Therapies. The Specialty Pharmaceuticals segment offers products for the treatment of attention deficit and hyperactivity disorder, including VYVANSE, a pro-drug stimulant; INTUNIV, a alpha-2A receptor; EQUASYM; DAYTRANA, a methylphenidate transdermal delivery system; and ADDERALL XR. It also produces PENTASA and LIALDA/MEZAVANT for the induction of remission and for the treatment of active ulcerative colitis; and FOSRENOL for use in end-stage renal failure patients receiving dialysis. In addition, this segment provides CALCICHEW, a range of calcium and calcium/vitamin D3 supplements; CARBATROL, an anti-convulsant for individuals with epilepsy; REMINYL/REMINYL XL for the symptomatic treatment of dementia of the Alzheimer type; and XAGRID for the reduction of elevated platelet counts, as well as for the treatment of thrombocythemia. The Human Genetic Therapies segment offers REPLAGAL for Fabry disease; ELAPRASE for the treatment of hunter syndrome; and FIRAZYR for hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and Hepatitis B. Further, it owns METAZYM, a Phase 1b completed products for enzyme replacement therapy program for the treatment of Metachromatic Leukodystrophy. The company markets its products through distributors in North America, the Republic of Ireland, the United Kingdom, and internationally. It has a license agreement with Mochida Pharmaceutical Co., Ltd. to develop and sell Lialda in Japan. The company has collaboration agreements with Santaris Pharma A/S, Renovo Limited, Alba Therapeutics Corporation, and Amicus. Shire plc was founded in 1986 and is based in Dublin, the Republic of Ireland.
Shire plc (SHPGY) Stock Key Statistics Research and Analysis as of May 18, 2012
| Stock Exchange | NasdaqNM |
| Market Capitalization | $16.745B
|
| Trade Volume (Average Trading Volume) | 490,898 (547,794) |
| Price/Sales | 3.81 |
| Price/Book | 4.83 |
| P/E | 19.68 |
| Earning/Share | $4.659 |
| Current Year EPS Estimate | $6.17 |
| Next Year EPS Estimate | $6.96 |
| Previous Closing Price | $91.69 |
| 50 Day Price Moving Average | $96.04 |
| 200 Day Price Moving Average | $99.65 |
| Dividend Yield | 0.49% |
| 1 yr Target Price | $113.08 |
| Ex-Dividend Date | Mar 7 |
| PEG Ratio | 1.12 |
| Short Ratio | 0.90 |
| EBITDA | $1.500B |
Shire plc (SHPGY) Stock Competitor Research and Analysis
Mutual Funds with Shire plc (SHPGY) Stock in its top 10 holdings
Stock Research on Shire plc (SHPGY)
Latest Market News on Shire plc (SHPGY)
Click here to find the latest news on Shire plc (SHPGY)
Looking for Market Opportunties?
Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center
See other companies in the same industry
Johnson & Johnson (JNJ) Novartis AG (NVS)
Research on Shire plc (SHPGY)
